Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines

NCT03014635 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
306
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Revance Therapeutics, Inc.